Articles from Agenus Inc.

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilimab (BOT) in combination with balstilimab (BAL) in patients with relapsed/refractory (R/R) metastatic sarcomas.

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today shared new data on botensilimab (BOT) and balstilimab (BAL) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco. Data from five presentations underscore the transformative potential of BOT/BAL across multiple lines of therapy in colorectal cancer, including neoadjuvant, first-line, and refractory settings. Data presented also highlight BOT/BAL’s potential in treating microsatellite stable (MSS) CRC tumors, which account for 85-95%1 of patients living with CRC that historically have been unresponsive to immuno-oncology (I/O) therapies. To date, BOT/BAL has been evaluated in approximately 1,100 patients across more than 60 centers worldwide.

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced five presentations featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (BAL, an anti-PD-1 antibody) at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium. The conference will take place on January 23-25, 2025, in San Francisco, California.

Agenus Inc., a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, strengthening its financial position, and prioritizing the advancement of its most impactful programs as it prepares for 2025. Reductions are designed to reduce cash burn to $100 million in FY 2025. This initiative follows the successful closing of a $22 million mortgage secured by key real estate assets, providing the company with enhanced operational flexibility during this pivotal period.

Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation has successfully secured a $22 million non-amortizing mortgage backed by its Berkeley-based Biologics CMC facility ("901 Heinz") and its 66-acre biomanufacturing-zoned property in Vacaville, California. Facilitated by L&L Capital, the transaction yields $20 million in net proceeds after closing costs and interest reserve, bolstering the company’s cash position ahead of anticipated additional cash infusions in the coming months. The mortgage, structured with a two-year term, carries interest payable in a 50% cash and 50% common stock arrangement, with rates set at 12% for Year 1 and 13% for Year 2.

Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial results for the third quarter of 2024.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the presentation of new data on two of its promising investigational immunotherapy candidates, botensilimab and AGEN1721, at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting in Houston, Texas. The data, showcasing potential breakthroughs in treating immune-resistant tumors, will be presented by Dhan Chand, Ph.D., Vice President of Research at Agenus.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2024 financial results before the market opens on Tuesday, November 12th, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, presented data today at the European Society for Medical Oncology (ESMO) Congress held in Barcelona, Spain. The data from a Phase 1 study of botensilimab (BOT), an investigational Fc-enhanced CTLA-4 inhibitor, in combination with balstilimab (BAL), an investigational PD-1 antibody, showed clinical activity in patients with refractory sarcomas, a population with limited treatment options.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that updated data from the clinical trial of botensilimab and balstilimab in refractory sarcomas will be featured in a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress, taking place September 13-17, 2024, in Barcelona, Spain.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Agenus executives, Dr. Garo Armen, Chief Executive Officer, Robin Taylor, Chief Commercial Officer, and Zack Armen, Head of Investor Relations, will participate in the following upcoming investor conferences:

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the second quarter of 2024.

Agenus Inc. (NASDAQAGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising, branding, and strategic advising.

Agenus Inc. (NASDAQAGEN), a leader in developing novel immunological agents to treat various cancers, today announced the publication of a seminal study in the prestigious Cancer Discovery, a journal of the American Association for Cancer Research, detailing the novel mechanism of action and effectiveness of botensilimab, an investigational, novel multifunctional anti-CTLA-4 antibody, in various treatment-resistant cancers.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.

Agenus Inc. (NASDAQAGEN), a leader in developing novel immunological agents to treat various cancers, today announced the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-sponsored trial (IST) of botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting for colon cancer. Data were presented at the 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Munich, Germany.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using botensilimab (BOT), a human Fc enhanced next-generation anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibody, which is being developed by CTEP as an anticancer agent in collaboration with Agenus Inc. CTEP will also consider requests to supply botensilimab for nonclinical studies. All clinical and nonclinical researchers interested in working with the agent are welcome to apply. All proposals approved by CTEP will be sent to the industry collaborator for a commitment to supply drug for the study.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the President and CEO of MiNK Therapeutics, in addition to her responsibilities as Chairman of the Executive Council at Agenus. Her continued leadership at MiNK ensures a seamless integration of strategic insights across both organizations, enhancing our collaborative efforts to innovate and deliver breakthrough cancer therapies.

Agenus Inc. (“Agenus”) (NASDAQAGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 11, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 10:15 a.m. ET.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted inducement awards to Eric Olson, in connection with his appointment as Head of Regulatory. The Compensation Committee approved the awards pursuant to Agenus' 2015 Inducement Equity Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced a novel analysis from the Phase 1b trial of botensilimab in combination with balstilimab (BOT/BAL) in relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM) will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024. The analysis shows that BOT/BAL is active in metastatic sites beyond the lungs and lymph nodes, including the peritoneum, soft tissue, and brain, which have historically been unresponsive to treatment.

Agenus Inc. (“Agenus”) (NASDAQAGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, and Robin Taylor, Chief Commercial Officer, will participate in a fireside chat and investor one-on-ones at the upcoming Goldman Sachs Global Healthcare Conference on June 10th – 13th in Miami Beach, Florida. The fireside chat will take place at 8:00 a.m. ET on June 12th.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced it will conduct a Type B End-of-Phase 2 (EOP2) meeting in July with the U.S. Food and Drug Administration (FDA) to discuss the botensilimab plus balstilimab (BOT/BAL) combination therapy studies in patients with relapsed/refractory metastatic colorectal cancer that is not MSI-high or dMMR (r/r MSS mCRC), as well as the critical elements of the program to support a future biologics license application (BLA) submission.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the first quarter 2024. In a concurrent press release accompanying Agenus’ earnings announcement, a $100M royalty financing agreement between Ligand and Agenus was reported. This pivotal, minimally dilutive capital infusion will support the key development and launch readiness initiatives needed to advance the company’s lead program, BOT/BAL, in relapsed/refractory non-MSI high colorectal cancer without liver metastases (r/r MSS CRC NLM).

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immunology-based therapies for cancer, received notice from NASDAQ on April 30, 2024, that the Company has regained compliance with the $1.00 minimum bid price requirement set forth in NASDAQ Listing Rule 5550(a)(2). Accordingly, the Company now satisfies all requirements for continued listing on the NASDAQ Capital Market and the matter is now closed.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced an upcoming presentation from the Phase 1b trial of botensilimab in combination with balstilimab (“BOT/BAL”) in patients with relapsed/refractory microsatellite stable colorectal cancer with no active liver metastases (r/r MSS CRC NLM) will be presented at the upcoming American Society of Clinical Oncology (ASCO) Meeting, to be held May 31 – June 4, 2024, in Chicago, IL. The poster presentation is for a sub-analysis of the r/r MSS CRC cohort of the Phase 1b study. This sub-analysis was done to determine whether treatment outcomes are correlated with specific sites of metastatic disease in patients with non-active liver mets.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.

Agenus Inc. (NASDAQAGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced updated results from its Phase 1 clinical trial of BOT/BAL combination therapy in patients with metastatic CRC that is not microsatellite instability-high (MSS) or deficient mismatch repair (dMMR). These findings build upon the compelling clinical activity demonstrated by BOT/BAL across nine different cancer types in Agenus' broad clinical development program.

Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced its stockholders have approved a one-for-twenty reverse stock split of its issued and outstanding common stock, which will go into effect at 12:01 a.m., Eastern Time on April 12, 2024. The reverse stock split is intended to give Agenus greater flexibility in its future financing needs and to increase the per share trading price of Agenus’ common stock to satisfy the minimum price requirement for continued listing on the Nasdaq Capital Markets and to qualify for inclusion in the Russell Indices. Agenus expects that upon the opening of trading on April 12, 2024, its common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under the current trading symbol “AGEN” and the new CUSIP number 00847G 804.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the first preclinical data from BMS-986442 (AGEN1777) will be presented in an oral presentation at the upcoming AACR Meeting, to be held April 5 – 10, 2024 in San Diego, CA.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted inducement awards to Nils Eckardt, Kent Barnes, and Brian Greenblatt, in connection with their appointments as Chief Medical Affairs Officer, Head of Marketing and Sales, and Vice President Commercial Operations and Business Analytics, respectively. The Compensation Committee approved the awards pursuant to Agenus' 2015 Inducement Equity Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Company will release its fourth quarter and year end 2023 financial results before the market opens on Thursday, March 14, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Leerink Global Biopharma Conference on March 11th - 13th in Miami Beach, Florida. The fireside chat will take place at 2:30 p.m. ET on March 11th.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Oppenheimer Healthcare Conference on February 13th - 14th. The fireside chat will take place at 8:00 a.m. ET on February 14th.

Agenus Inc. (Nasdaq: AGEN), a leader in developing immunological cancer treatments, today announced results from the NEST-1 study, an investigator-sponsored trial (IST) evaluating the combination of botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting for colorectal cancer (CRC), both those with Microsatellite Stable (MSS) CRC and Microsatellite Instability High (MSI-H) CRC. Dr. Pashtoon Kasi, M.D., Director of Colon Cancer Research at Weill-Cornell Medicine, presented these findings at the ASCO-GI conference.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted, as of January 2, 2024 (“Grant Date”), inducement awards to Manuel Duenas and Benny Johnson in connection with their appointments as Head of Market Access and Senior Medical Director, respectively. The Compensation Committee approved the awards pursuant to Agenus' 2015 Inducement Equity Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming B. Riley Virtual Healthcare Conference on January 18th. The fireside chat will take place at 3:00 p.m. ET on January 18th.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that data from an investigator sponsored trial (IST) evaluating botensilimab (BOT, multifunctional CTLA-4 immune activator) in combination with balstilimab (BAL, PD-1 antibody) in neoadjuvant colorectal cancer (CRC) will be presented at the upcoming ASCO-GI Meeting, to be held January 18 – 20, 2024 in San Francisco, CA. The IST is led by Pashtoon Kasi, M.D., who was recruited to Weill Cornell Medicine as an associate professor of medicine and is a member of its Sandra and Edward Meyer Cancer Center. Dr. Kasi is also an oncologist at NewYork Presbyterian/Weill Cornell Medical Center.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced it has triggered the second development milestone payment under its global licensing agreement with Bristol Myers Squibb for BMS-986442, an Fc-enhanced bispecific TIGIT antibody. Agenus will receive a $25 million cash payment from Bristol Myers Squibb with the dosing of the first patient in the phase 2 dose expansion portion of the ongoing CA115-001 clinical trial of BMS-986442.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the third quarter 2023. Agenus executives will host a conference call and webcast at 9:00 a.m. ET to discuss the results and to provide a corporate update.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2023 financial results via press release before the market opens on Tuesday, November 7, 2023.

Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat cancers, today announced first-time and updated data from its ongoing botensilimab/balstilimab (BOT/BAL) clinical programs in advanced colorectal cancer (CRC), neoadjuvant CRC, pancreatic cancer, non-small cell lung cancer (NSCLC), melanoma, and sarcoma. Members of the Agenus leadership team along with key opinion leaders will discuss these findings during a live webcast at 1:00 p.m. EDT (19:00 CEST) at a corporate event at the European Society for Medical Oncology 2023 Conference.

Agenus Inc. (Nasdaq:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced expanded data from the company’s phase 1b study of botensilimab (BOT, multifunctional immune activator) in combination with balstilimab (BAL, anti-PD-1) in patients with advanced sarcomas. The results were presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023.

Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers today announced completion of the planned patient enrollment in ACTIVATE-Colorectal, a randomized Phase 2 trial in advanced colorectal cancer (CRC) evaluating the efficacy and safety of botensilimab (BOT) as monotherapy and in combination with balstilimab (BAL) or standard of care in patients with metastatic heavily pre-treated colorectal cancer.

Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Company will host a corporate event to discuss advancements in its botensilimab/balstilimab (BOT/BAL) program at the upcoming European Society for Medical Oncology (ESMO) Conference on Sunday, October 22, 2023. Agenus will provide updates from the ongoing BOT/BAL clinical program, including in neoadjuvant colorectal cancer and pancreatic cancer. A live webcast of the event will be available.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus’ Board of Directors granted, as of September 1, 2023 (“Grant Date”), inducement awards to Robin Taylor, Ph.D. in connection with his appointment as Chief Commercial Officer. The Compensation Committee approved the awards pursuant to Agenus' 2015 Inducement Equity Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in the following upcoming investor conferences:

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a pioneer in immuno-oncology, today announced a strategic initiative to prioritize and focus resources to accelerate the development, registration, and commercialization of its flagship program botensilimab/balstilimab (BOT/BAL). Under this new plan, Agenus will temporarily postpone all preclinical and clinical programs not related to BOT/BAL. The plan will result in a workforce reduction of approximately 25% and deliver approximately $40 million in savings by the end of 2023.

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results for the second quarter 2023.

Immuno-oncology leader, Agenus Inc. (“Agenus”) (Nasdaq: AGEN), today announced a data update from the phase 1 expansion cohort of botensilimab (multifunctional CTLA-4 antibody) in combination with balstilimab (PD-1 antibody) for patients with advanced, refractory sarcomas has been selected for an oral presentation at the upcoming ESMO Congress, to be held October 20 – 24, 2023 in Madrid, Spain.

Immuno-oncology leader, Agenus Inc. (“Agenus”) (Nasdaq: AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team. The newly appointed leaders bring a wealth of industry experience to drive the company’s next phase of growth in the development and planned commercialization of botensilimab and a deep pipeline of immuno-oncology programs, which offer potential breakthroughs in cancer therapeutics.

Agenus (Nasdaq: AGEN), a leading immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, presented complete results from the monotherapy arm of the first-in-human dose escalation study of AGEN2373 (CD137 agonist) at the American Society of Clinical Oncology (ASCO) Annual Meeting. AGEN2373 demonstrated objective responses, clinical benefit, and was well tolerated in heavily pre-treated patients with solid tumors.

Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with an extensive pipeline of clinical and preclinical-stage cancer treatments, today provided a corporate update and reported financial results for the first quarter 2023.

Agenus Inc. (Nasdaq: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, has been granted Fast Track Designation from the US Food and Drug Administration (FDA) for the investigation of the combination of botensilimab (AGEN1181) and balstilimab (AGEN2034). The designation is for patients with non-microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) metastatic colorectal cancer with no active liver involvement. Patients targeted with this designation are heavily pretreated are resistant or intolerant to a fluoropyrimidine, oxaliplatin, and irinotecan, and who have also received a VEGF inhibitor, an EGFR inhibitor and/or a BRAF inhibitor, if indicated. The company is conducting a global, randomized Phase 2 trial of botensilimab in combination with balstilimab compared to standard of care in non-microsatellite instability-high (non-MSI-H) colorectal cancer patients.

Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that its Board of Directors has declared a dividend of 5 million shares of common stock of its subsidiary, MiNK Therapeutics, Inc. (“MiNK”), to shareholders of Agenus as of April 17, 2023 (the “Record Date”). MiNK is a clinical-stage precision oncology company developing allogeneic, invariant natural killer T cell therapies and operates as a separate publicly traded company.

Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced results from a cohort of 24 evaluable patients in an expansion of the Company’s Phase 1b study of botensilimab (multifunctional CTLA-4 antibody) in combination with balstilimab (PD-1 antibody) in patients with recurrent platinum resistant/refractory ovarian cancer. These findings, presented in an oral plenary session at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, showed a 33% overall response rate (ORR).

LEXINGTON, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today provided a corporate update and reported financial results for the fourth quarter and full year 2022.

Conference Call Cancelled

Conference Call on Monday, March 13, 2023 at 8:30 a.m. ET

Conference Call on Tuesday, March 14, 2023 at 8:30 a.m. ET

LEXINGTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, today announced plans to present updated data on its lead program botensilimab (Fc-enhanced anti-CTLA-4), at the Society of Gynecologic Oncology (SGO) 37th Annual Meeting on Women’s Cancer, to be held March 25-28 in Tampa, FL. Updated data from an expansion cohort of the Phase 1 study of botensilimab in combination with balstilimab (anti-PD-1) in patients with recurrent platinum refractory/resistant ovarian cancer will be presented at an oral plenary session on Monday, March 27th at 9:18am ET.

LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Agenus (NASDAQAGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO, and Dr. Steven O’Day, Chief Medical Officer, will participate in the following upcoming investor conferences:

LEXINGTON, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced clinical data from the MSS CRC (microsatellite stable colorectal cancer) 70 patient cohort of a Phase 1b study of botensilimab (multifunctional Fc-enhanced anti-CTLA-4) in combination with balstilimab (anti-PD-1) in patients with chemotherapy and/or immunotherapy-resistant tumors. The larger dataset continues to demonstrate that this combination offers superior efficacy and durability compared to what has been reported for standard of care and other investigational therapies in third line metastatic MSS CRC. The data were presented in the opening late-breaking oral session at the American Society of Clinical Oncology – Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, CA on Saturday Jan 21 2023.

LEXINGTON, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Agenus (NASDAQAGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO of Agenus, and Dr. Steven O’Day, Chief Medical Officer, will participate in a virtual fireside chat at the B Riley Securities’ 2023 Virtual Oncology Conference on Wednesday, January 18th at 11:30am ET.

LEXINGTON, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQAGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will present expanded data on botensilimab in combination with balstilimab at the American Society of Clinical Oncology – Gastrointestinal Cancers Symposium (ASCO-GI), to be held January 19-21, 2023, in San Francisco, CA.

LEXINGTON, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, announced expanded data from the Company’s Phase 1 study of botensilimab (Fc-enhanced anti-CTLA-4) and balstilimab (anti-PD-1) in patients with advanced sarcoma. The data demonstrate that the combination offers strong durability and superior efficacy compared to what has been reported in separate trials for standard of care and other investigational therapies in sarcoma, including in sarcoma subtypes historically unresponsive to immunotherapy. The results will be presented tomorrow in an oral presentation at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting in Vancouver, BC, Canada.

LEXINGTON, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQAGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO of Agenus, and Dr. Steven O’Day, Chief Medical Officer, will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30th at 12:35pm ET. The Conference will be held virtually from November 29th – December 1st, during which Agenus will host one-on-one meetings with investors.

LEXINGTON, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, announced expanded data from the Company’s Phase 1 study of botensilimab (Fc-enhanced anti-CTLA-4) and balstilimab (anti-PD-1) in patients with treatment-resistant tumors, including MSS-CRC, ovarian, sarcoma and NSCLC. The data presented represents four of the most mature data sets from the nine cancer types where responses have been observed to date. The data was presented at a plenary session at the Society for Immunotherapy of Cancer (SITC) annual meeting and a company-hosted R&D event.

LEXINGTON, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQAGEN), an immuno-oncology company with a broad pipeline targeting cancers and infectious disease, today provided a corporate update and reported financial results for the third quarter of 2022.

LEXINGTON, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQAGEN) an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will release its second quarter 2022 financial results before the market opens on Tuesday, November 8, 2022. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.

LEXINGTON, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQAGEN), an immuno-oncology company with an extensive pipeline of therapies and adjuvants designed to activate the immune response to cancer and infections, today shared that GSK has disclosed positive pivotal phase III trial results for its respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above and plans to present full data at ID Week on October 20th. The vaccine candidate was highly efficacious, demonstrating overall vaccine efficacy of 82.6% (96.95% CI, 57.9–94.1) against RSV lower respiratory tract disease (RSV-LRTD), meeting the trial’s primary endpoint.

CAMBRIDGE, Mass. and LEXINGTON, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) --  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, and Agenus (NASDAQAGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced a collaboration to evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic, and balstilimab, Agenus’ monoclonal antibody (mAb) targeting the programmed death receptor-1 (PD-1) protein, in primary glioblastoma (GBM) patients as part of the adaptive platform trial, INSIGhT. Under the agreement, VBI will be the study sponsor and will be responsible for operational execution of the combination trial, and Agenus will provide drug supply and scientific support.

LEXINGTON, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQAGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced it will host an in-person and virtual Research & Development event (“The Road Taken”) on Saturday, November 12, 2022, from 2:00 p.m. to 5:00 p.m. ET at the Prudential Tower in Boston, MA.